FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA and CMS Outline Initiatives to Support Gene Therapy Development and Improve Access for People with Rare Diseases

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • October 27, 2026

Share

  • 1

    FDA issued draft guidance outlining a regulatory framework for individualized genome-editing products intended to treat rare genetic diseases.

  • 2

    The guidance’s Individualized Feature Space defines allowable variation among patient-specific products that may be included in one Biologics License Application.

  • 3

    Sponsors may add variants within the defined limits through a streamlined review using laboratory data, without conducting additional clinical trials.

  • 4

    The draft guidance addresses manufacturing, safety testing, product naming, and labeling while maintaining FDA standards for safety and effectiveness.

  • 5

    CMS plans to expand its voluntary Medicaid Cell and Gene Therapy Access Model beyond sickle cell disease through manufacturer applications and outcomes-based agreements.

Original Source(s)

FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases

  • by Assistant Secretary for Public Affairs (ASPA)

  • October 27, 2026

Related Content

Outdoor artificial nighttime light may raise childhood myopia risk

Higher exposure was associated with new-onset myopia over 3 years, with risk increasing sharply at higher nighttime light levels.

Evaluation of the Square Eyes Model as a Screening Tool for Identifying Digital Technologies in Wearable Camera Images Among Children: Laboratory Study

FDA approves new treatment for FOP

Total new heterotopic ossification volume decreased with treatment and increased with placebo at week 24.